Inventor · disambiguated record
Robert A. Volkmann
Also filed as: VOLKMANN ROBERT A · VOLKMANN Robert
74 granted patents·12 pending applications·471 citations·filing 1982–2024
99Inventor score
Top patents by PatentIndex Score
86 records- 0198US11236102B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2020·Granted Feb 1, 2022·5 cites·9 claims
- 0296US11236104B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2020·Granted Feb 1, 2022·4 cites·28 claims
- 0396US10618908B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2019·Granted Apr 14, 2020·6 cites·11 claims
- 0495US10364252B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2018·Granted Jul 30, 2019·7 cites·19 claims
- 0595US9988394B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2016·Granted Jun 5, 2018·7 cites·16 claims
- 0694US10626122B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 21, 2020·8 cites·16 claims
- 0793US10500205B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Dec 10, 2019·10 cites·22 claims
- 0892US11866444B2Oxabicycloheptane prodrugsLIXTE BIOTECHNOLOGY INC·Filed 2022·Granted Jan 9, 2024·1 cites·10 claims
- 0991US12145909B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BNOVARTIS AG·Filed 2022·Granted Nov 19, 2024·1 cites·21 claims
- 1091US10752633B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Aug 25, 2020·9 cites·5 claims
- 1191US10584131B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2019·Granted Mar 10, 2020·9 cites·2 claims
- 1290US12161624B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·1 cites·20 claims
- 1390US11807650B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2022·Granted Nov 7, 2023·1 cites·17 claims
- 1490US11634508B2Peptide conjugates of cytotoxins as therapeuticsCYBREXA 2 INC·Filed 2020·Granted Apr 25, 2023·3 cites·16 claims
- 1590US11555019B2Peptide conjugates of microtubule-targeting agents as therapeuticsCYBREXA 3 INC·Filed 2020·Granted Jan 17, 2023·3 cites·21 claims
- 1690US10973825B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2016·Granted Apr 13, 2021·6 cites·16 claims
- 1790US4703052AHypoglycemic thiazolidinedionesPFIZER·Filed 1985·Granted Oct 27, 1987·79 cites·19 claims
- 1889US6057364AFluoro-substituted adamantane derivativesPFIZER·Filed 1998·Granted May 2, 2000·40 cites·11 claims
- 1987US11541057B2Thienopyrimidinone NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
- 2087US11274107B2NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2017·Granted Mar 15, 2022·3 cites·20 claims
- 2187US10933069B2Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissuesCYBREXA 1 INC·Filed 2019·Granted Mar 2, 2021·6 cites·29 claims
- 2287US9963434B2N-arylmethyl sulfonamide negative modulators of NR2ALUC THERAPEUTICS·Filed 2014·Granted May 8, 2018·8 cites·25 claims
- 2386US11542264B2Heteroaromatic NMDA receptor modulators and uses thereofCADENT THERAPEUTICS INC·Filed 2021·Granted Jan 3, 2023·1 cites·2 claims
- 2485US4864046AProcess for optically active 3-thiolanyl sulfonate estersPFIZER·Filed 1989·Granted Sep 5, 1989·18 cites·3 claims
- 2584US4739047AIntermediates for 2-(1-oxo-3-thiolanyl)-2-penem antibioticsPFIZER·Filed 1986·Granted Apr 19, 1988·22 cites·7 claims
- 2683US4738972AHypoglycemic thiazolidinedionesPFIZER·Filed 1987·Granted Apr 19, 1988·18 cites·23 claims
- 2782US5227397APolyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channelsPFIZER·Filed 1990·Granted Jul 13, 1993·19 cites·28 claims
- 2882US2025034145A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2981US12358929B2NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Granted Jul 15, 2025·0 cites·14 claims
- 3081US10781174B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2BCADENT THERAPEUTICS INC·Filed 2019·Granted Sep 22, 2020·1 cites·31 claims
- 3180US2024199617A1Heteroaromatic nmda receptor modulators and uses thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3279US5185369ASynthetic heteroaryl polyamines as excitatory amino acid neurotransmitter antagonistsPFIZER·Filed 1991·Granted Feb 9, 1993·19 cites·2 claims
- 3377US5013729ADiastereomeric 5R,6S-6-(1R-hydroxyethyl)-2-(cis-1-oxo-3-thiolanylthio)-2-penem-3-carboxylic acidsPFIZER·Filed 1987·Granted May 7, 1991·18 cites·12 claims
- 3476US12162890B2Heteroaromatic NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted Dec 10, 2024·0 cites·31 claims
- 3574US11648253B2Thienopyrimidinone NMDA receptor modulators and uses thereofNOVARTIS AG·Filed 2021·Granted May 16, 2023·0 cites·19 claims
- 3674US5191077ADiastereomeric 5R,6S-6-(1R-hydroxyethyl)-2-(cis-1-oxo-3-thiolanylthio)-2-penem-3-carboxylic acidsPFIZER·Filed 1991·Granted Mar 2, 1993·13 cites·5 claims
- 3773US5037846AIndolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmittersPFIZER·Filed 1990·Granted Aug 6, 1991·26 cites·21 claims
- 3873US4940823AProcess for optically active 3-thiolanyl sulfonate estersPFIZER·Filed 1990·Granted Jul 10, 1990·12 cites·1 claims
- 3971US11116749B2Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2BCADENT THERAPEUTICS INC·Filed 2018·Granted Sep 14, 2021·0 cites·9 claims
- 4071US10239835B2N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2BLUC THERAPEUTICS INC·Filed 2015·Granted Mar 26, 2019·1 cites·22 claims
- 4170US2020369610A1N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2bCADENT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4269US12410262B2Peptide conjugates of cytotoxins as therapeuticsCYBREXA 2 INC·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 4369US12234212B2Peptide conjugates of microtubule-targeting agents as therapeuticsCYBREXA 3 INC·Filed 2023·Granted Feb 25, 2025·0 cites·22 claims
- 4469US5122596APolypeptides useful as blockers of calcium channelsPFIZER·Filed 1989·Granted Jun 16, 1992·15 cites·2 claims
- 4568US4468516AProcess for the preparation of biotinPFIZER·Filed 1982·Granted Aug 28, 1984·6 cites·8 claims
- 4662US5319103AIntermediate diastereomeric 5R,6S-6-(1R-hydroxyethyl)-2-(cis-1-oxo-3-thiolanylthio)-2-penem-carboxylic acidsPFIZER·Filed 1993·Granted Jun 7, 1994·12 cites·10 claims
- 4761US10242091B2Method of knowledge extraction through data miningSYSTAMEDIC INC·Filed 2014·Granted Mar 26, 2019·1 cites·22 claims
- 4859US4870170AProcess for 2-(1-oxo-3-thiolanyl)-2-penem antibioticsPFIZER·Filed 1988·Granted Sep 26, 1989·5 cites·8 claims
- 4958US4588527AProcess for preparing penicillanic acid 1,1-dioxide derivativesPFIZER·Filed 1984·Granted May 13, 1986·4 cites·11 claims
- 5056US12427157B2Methods for treatment of diseases involving acidic or hypoxic diseased tissuesCYBREXA 1 INC·Filed 2020·Granted Sep 30, 2025·0 cites·29 claims
Showing the top 50 of 86 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Robert A. Volkmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →